A commercial payer does not pay Medicare's ASP+6% benchmark for a provider-administered drug. It pays a contracted rate that its network negotiated directly with the billing provider, and that rate is set independently by payer, state, and even by which specific provider contract applies. Since 2022, federal price transparency rules require most plans to publish these rates in machine-readable files, which is how a rate can be looked up before a claim is filed rather than guessed from Medicare's number. Drug administration is billed separately from the drug itself, and a claim's total is the sum of both lines.
Medicare's ASP+6% is a single, public number recalculated by CMS every quarter from manufacturers' actual average sales price data, and it applies uniformly to every Part B claim nationwide. A commercial payer's rate is nothing like that: it is a bilateral number, set in a provider contract negotiated between one payer and one network, and it is never assumed to equal the Medicare benchmark in either direction. A commercial rate can land above ASP+6%, below it, or by coincidence close to it — the only way to know is to check that specific payer's own published rate for that specific drug code.
A commercial reimbursement rate is the output of a specific negotiation, so it moves with everything that shapes that negotiation: the payer's size and leverage in a given market, the strength of the provider network being contracted with, local cost-of-care benchmarks, and the payer's own internal drug reimbursement policy. None of those inputs are national, which is why the same payer routinely prices the identical HCPCS code differently from state to state — and sometimes from one provider contract to another within the same state.
The federal Transparency in Coverage rule, in effect since July 2022, requires most commercial health plans and issuers to publish machine-readable files listing the negotiated rate for every billing code in every provider contract they hold. These files are large, technical, and not built for a human reader — this site's corpus parses and indexes them by payer, state, and HCPCS code so a practice can look up a specific drug's contracted rate directly, instead of waiting for a remittance advice to find out after the claim has already been filed.
A provider-administered drug always generates at least two claim lines: the drug itself, billed by its HCPCS or J-code and unit count, and the administration service, billed by a CPT code for the infusion or injection (plus a separate office-visit code when a significant, separately identifiable evaluation is documented). Each line carries its own allowed amount under a payer's published price file — the drug rate and the administration rate are never a single bundled figure, under Medicare or under a commercial contract.
A commercial infusion or injection claim's total allowed amount is the drug line (billed units times the payer's contracted per-unit rate) plus every administration line billed alongside it. That total is the starting point, not the answer, for what the patient owes: the patient's actual responsibility still depends on their specific plan's deductible status, coinsurance percentage, and remaining out-of-pocket maximum for the year — figures a price file does not itself contain.
Medicare pays a public, uniform benchmark for most Part B drugs: ASP+6%, recalculated every quarter from CMS's average sales price file. A commercial payer instead pays whatever rate it negotiated with a specific provider in its network contract, which can be higher or lower than the Medicare benchmark and is never assumed to equal it. Two commercial payers — or the same payer in two different provider contracts — can pay meaningfully different amounts for the identical drug and code.
A commercial rate is the product of a specific contract negotiated between one payer and one provider network, so it reflects that network's negotiating leverage, the local cost of care, and the payer's own reimbursement policy for that drug class — none of which are uniform across the country the way a federal ASP benchmark is. The same payer frequently prices the same drug differently state to state, and even market to market within a state, because it holds separate provider contracts in each one.
Since 2022, the federal Transparency in Coverage rule requires most commercial health plans to publish machine-readable files listing the negotiated rate for every code in every provider contract. These files are the source for the payer-published reimbursement rates shown throughout this site — they let a practice see a payer's actual contracted rate for a drug's HCPCS code before a claim is ever filed, instead of guessing from a remittance advice after the fact.
Yes. The drug (billed by its HCPCS/J-code and unit count) and the administration service (billed by a CPT code such as an infusion or injection administration code) are two separate claim lines with two separate allowed amounts, exactly as they are under Medicare. A payer's published price file typically lists a rate for the drug code and, separately, a rate for the administration code — they are not bundled into one number.
A commercial infusion or injection claim total is the sum of the drug line (HCPCS/J-code times billed units, at the payer's contracted rate) plus one or more administration lines (CPT codes for the infusion or injection service, and any separately billed office visit). What the patient owes out of that total then depends on their specific plan design — deductible status, coinsurance percentage, and out-of-pocket maximum — which a payer's published price file does not itself describe.
Not reliably. The Medicare ASP+6% rate is a useful public benchmark for comparison, and some commercial rates land close to it, but a commercial payer is free to negotiate above or below that benchmark, and different payers in the same market routinely diverge from each other as well as from Medicare. The only way to know a specific payer's rate for a specific drug is to check that payer's own published price file or provider contract.
All sources are publicly available federal publications or payer-published price files. The methodology by which we resolve source disagreements is described in the Methodology.